pentoxifylline has been researched along with Bisphosphonate Osteonecrosis in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Evaluate the effect of pentoxifylline and α-tocopherol administration in the prevention or treatment of medication-related jaw osteonecrosis (MRONJ)." | 8.12 | Effect of pentoxifylline and α-tocopherol on medication-related osteonecrosis of the jaw in rats: Before and after dental extraction. ( Andreis, JD; Claudino, M; Delfrate, G; Fernandes, D; Franco, GCN; Lipinski, LC; Mecca, LEA; Mroczek, T, 2022) |
| "Zoledronic acid is a third-generation nitrogen-containing BP." | 5.40 | Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis. ( Magremanne, M; Reychler, H, 2014) |
| " Interest in pentoxifylline and tocopherol is growing because these agents have been shown to be effective in treating osteoradionecrosis of the jaw." | 5.01 | Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw. ( Abdelsamie, S; Campbell, CB; Fielding, AF; Heifetz-Li, JJ; Mulligan, JP; Roth, S, 2019) |
| "Evaluate the effect of pentoxifylline and α-tocopherol administration in the prevention or treatment of medication-related jaw osteonecrosis (MRONJ)." | 4.12 | Effect of pentoxifylline and α-tocopherol on medication-related osteonecrosis of the jaw in rats: Before and after dental extraction. ( Andreis, JD; Claudino, M; Delfrate, G; Fernandes, D; Franco, GCN; Lipinski, LC; Mecca, LEA; Mroczek, T, 2022) |
| "Breast cancer was the most predominant neoplasm (70." | 1.91 | Pentoxifylline and tocopherol as prophylaxis for osteonecrosis of the jaw due to bone-modifying agents in patients with cancer submitted to tooth extraction: a case series. ( da Motta Silveira, FM; de Andrade Veras, SR; de Lima E Silva, DF; de Mello, MJG; Magalhães, JMI; Regueira, LS, 2023) |
| "Zoledronic acid is a third-generation nitrogen-containing BP." | 1.40 | Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis. ( Magremanne, M; Reychler, H, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Delfrate, G | 1 |
| Mroczek, T | 1 |
| Mecca, LEA | 1 |
| Andreis, JD | 1 |
| Fernandes, D | 1 |
| Lipinski, LC | 1 |
| Claudino, M | 1 |
| Franco, GCN | 1 |
| Magalhães, JMI | 1 |
| da Motta Silveira, FM | 1 |
| Regueira, LS | 1 |
| de Lima E Silva, DF | 1 |
| de Andrade Veras, SR | 1 |
| de Mello, MJG | 1 |
| Heifetz-Li, JJ | 1 |
| Abdelsamie, S | 1 |
| Campbell, CB | 1 |
| Roth, S | 1 |
| Fielding, AF | 1 |
| Mulligan, JP | 1 |
| Cavalcante, RC | 1 |
| Tomasetti, G | 1 |
| Magremanne, M | 1 |
| Reychler, H | 1 |
| Janovszky, Á | 1 |
| Vereb, T | 1 |
| Szabó, A | 1 |
| Piffkó, J | 1 |
| Owosho, AA | 1 |
| Estilo, CL | 1 |
| Huryn, JM | 1 |
| Yom, SK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ): A Prospective, Randomized Controlled Trial to Evaluate a Novel Non-operative Treatment[NCT03040778] | Phase 3 | 100 participants (Anticipated) | Interventional | 2018-04-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for pentoxifylline and Bisphosphonate Osteonecrosis
| Article | Year |
|---|---|
Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Humans; Osteor | 2019 |
Pentoxifylline and tocopherol protocol to treat medication-related osteonecrosis of the jaw: A systematic literature review.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates | 2020 |
[Current approaches for early detection and treatment of medication-related osteonecrosis of jaw].
Topics: alpha-Tocopherol; Analgesics; Anti-Bacterial Agents; Biomarkers; Bisphosphonate-Associated Osteonecr | 2014 |
4 other studies available for pentoxifylline and Bisphosphonate Osteonecrosis
| Article | Year |
|---|---|
Effect of pentoxifylline and α-tocopherol on medication-related osteonecrosis of the jaw in rats: Before and after dental extraction.
Topics: alpha-Tocopherol; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conserva | 2022 |
Pentoxifylline and tocopherol as prophylaxis for osteonecrosis of the jaw due to bone-modifying agents in patients with cancer submitted to tooth extraction: a case series.
Topics: Adolescent; Adult; Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservati | 2023 |
Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis.
Topics: Adrenal Cortex Hormones; Alendronate; Antioxidants; Bisphosphonate-Associated Osteonecrosis of the J | 2014 |
Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series.
Topics: Aged; Antioxidants; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Ag | 2016 |